Efficacy of transcatheter arterial chemoembolization combined with ganfule on advanced hepatocellular carcinoma

Hao, Mingzhi; Lin, Huilong; Chen, Qizhong; Hu, Yubin; Zhou, Dong; Huang, Ping; Ye, Yunbin

doi:10.1007/s10330-012-1099-1

Cited by 3 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study from Iowa on patients with NLMs showed that preoperative HACE followed by OLT can result favorably for the patients with progression-free intervals up to 29 months, but this was a small study, and statistical inferences could not be made due to the inclusion of only four patients [ 33 ]. Along a different treatment strategy, Hao et al showed that survival improved when patients with hepatocellular carcinoma received combination therapy with HACE plus thalidomide versus HACE alone [ 34 ]. This improvement reached statistically significant improvement, resulting in median overall survival increases of 15 months [ 34 ].…”

Section: Liver-directed Therapiesmentioning

confidence: 99%

“…Along a different treatment strategy, Hao et al showed that survival improved when patients with hepatocellular carcinoma received combination therapy with HACE plus thalidomide versus HACE alone [ 34 ]. This improvement reached statistically significant improvement, resulting in median overall survival increases of 15 months [ 34 ]. Similarly, in an experimental model utilizing liver tumors in rabbits, favorable outcomes resulting in significantly decreased vascular endothelial growth factor and microvascular density levels were achieved when HACE plus antiangiogenic therapies were used [ 35 ].…”

Section: Liver-directed Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review

Harring

Nguyen

Goss

et al. 2011

International Journal of Hepatology

View full text Add to dashboard Cite

Patients diagnosed with Neuroendocrine Tumors (NET) often are also diagnosed with Neuroendocrine Liver Metastases (NLM) during the course of their disease. NLM can cause significant morbidity and mortality, oftentimes much more than compared to patients with NET. Treatment options have been limited in the past, focusing on surgical resections, for which only a minority of patients are candidates. However, developments of new treatment modalities have progressed rapidly and patients with NLM now have significantly more options, including surgical-directed therapies; liver-directed therapies; and nonsurgical, non-liver-directed therapies. This review provides information about the roles of hepatic resection, orthotopic liver resection, radiofrequency ablation, hepatic artery embolization and hepatic artery chemoembolization, hepatic artery radioembolization and selective internal radiation therapy, peptide receptor radionuclide therapy, systemic chemotherapy, biotherapies including somatostatin analogs and interferon-α, vascular endothelial growth factor and mTOR targets, and microRNA-regulated pathways. Given these new options, the clinician can tailor therapy specific to the patient diagnosed with NLM, thereby giving the patient the best possible chance of prolonged survival.

show abstract

Section: Liver-directed Therapiesmentioning

confidence: 99%

Section: Liver-directed Therapiesmentioning

confidence: 99%

Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review

Harring

Nguyen

Goss

et al. 2011

International Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…As a famous medical prescription, GFL has an apparent effect on the treatment of HCC, hepatitis and cirrhosis (HAO et al, 2013). With the aid of systems biology and other means, this study first analysed and identified the chemical components of GFL through UPLC-QTOF/MS technology and assigned them to the prescription.…”

Section: Discussionmentioning

confidence: 99%

“…Modern pharmacological studies have also shown that GFL can be used in the treatment of advanced HCC to improve the quality of life and effectively control the development rate of HCC (Wang et al, 2018). GFL combined with transcatheter arterial chemoembolization (TACE) significantly prolongs overall survival in patients with advanced HCC (HAO et al, 2013). However, GFL is composed of a variety of TCM.…”

Section: Introductionmentioning

confidence: 99%

Effects of Ganfule capsule on microbial and metabolic profiles in anti-hepatocellular carcinoma

Pan

et al. 2022

Journal of Applied Microbiology

View full text Add to dashboard Cite

Aims: Based on the gut microbiota and plasma metabolites, the underlying mechanism was analysed for the anti-hepatocellular carcinoma (HCC) effects of Ganfule capsule (GFL) in the study. Methods and results:The UPLC-Q-TOF/MS results showed that 13 key compounds were identified in GFL and the major active ingredients included amygdalin, saikosaponin A, astragaloside I, etc. The nude mice received HepG2 injection, and GFL showed lower volume and weight of the tumour. In addition, the apoptosis proteins (Bax and Bcl2) were altered in response to GFL treatment, and apoptosis cells were increased, indicating an anti-HCC effect. Interestingly, 16S rDNA results showed that GFL treatment improved gut microbiota diversity and compositions, especially for the beneficial bacteria, such as Bacilli, Lactobacillales, Lactobacillus, Lactobacillaceae, Firmicutes, Lactobacillus_reuteri and Lactobacillus_gasseri.Metabonomics further identified 426 metabolites and 343 metabolites variation in the positive and negative ion modes after GFL treatment, which might be associated with amino acid, lipid metabolism and carbohydrate metabolism pathways, indicating these metabolites might involve in the protective role of GFL in HCC.Correlation analysis showed a significant relationship between gut microbiota and plasma metabolites. Conclusion:In conclusion, GFL exerted an anti-HCC effect in the nude murine model, which might be associated with microbial and metabolic improvements. Significance and impact of the study:This study is the first to report the anti-HCC effect of GFL associated with gut microbiota and plasma metabolites. GFL may improve the gut microbiota structure, such as increasing probiotics -Lactobacillus.It also provides a new strategy for the scientific demonstration of the modernization of traditional Chinese medicine.

show abstract

“…The mOS of the TACE combined with GFL group was 205 days, which was significantly higher than the 127 days of the TCM alone group. The 6-months, 1-year, and 2-years OS rates were 58.9, 29.1, and 7.7%, respectively, for the TACE combined with GFL group compared with 33.3%, 12.3%, and 1.8%, respectively, for the TCM alone group, but evidence supporting this combination regimen is still low, and further exploration is needed ( Hao et al, 2013 ).…”

Section: Chinese Patent Medicines In Primary Liver Cancermentioning

confidence: 99%

Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges

Xiao

Zhu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Primary liver cancer (PLC) is one of the most common solid malignancies. However, PLC drug development has been slow, and first-line treatments are still needed; thus, studies exploring and developing alternative strategies for effective PLC treatment are urgently needed. Chinese herbal medicine (CHM) has long been applied in the clinic due to its advantages of low toxicity and targeting of multiple factors and pathways, and it has great potential for the development of novel natural drugs against PLC.Purpose: This review aims to provide an update on the pharmacological mechanisms of Chinese patent medicines (CPMs) and the latest CHM-derived compounds for the treatment of PLC and relevant clinical evaluations.Materials and Methods: A systematic search of English literature databases, Chinese literature, the Clinical Trials Registry Platform, and the Chinese Clinical Trial Registry for studies of CHMs for PLC treatment was performed.Results: In this review, we summarize the clinical trials and mechanisms of CPMs for PLC treatment that have entered the clinic with the approval of the Chinese medicine regulatory authority. These CPMs included Huaier granules, Ganfule granules, Fufang Banmao capsules, Jinlong capsules, Brucea javanica oil emulsions, and compound kushen injections. We also summarize the latest in vivo, in vitro, and clinical studies of CHM-derived compounds against PLC: icaritin and ginsenoside Rg3. Dilemmas facing the development of CHMs, such as drug toxicity and low oral availability, and future developments are also discussed.Conclusion: This review provides a deeper the understanding of CHMs as PLC treatments and provides ideas for the development of new natural drugs against PLC.

show abstract

Efficacy of transcatheter arterial chemoembolization combined with ganfule on advanced hepatocellular carcinoma

Cited by 3 publications

References 14 publications

Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review

Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review

Effects of Ganfule capsule on microbial and metabolic profiles in anti-hepatocellular carcinoma

Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges

Contact Info

Product

Resources

About